|
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
|
August 9, 2022
|
PC3I Authors Melina Marmarelis; Ronac Mamtani |
Clinical Lung Cancer
|
|
A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma
|
September 29, 2022
|
PC3I Authors Melina Marmarelis |
PLoS One
|
|
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer
|
February 25, 2023
|
PC3I Authors Melina Marmarelis |
Clinical Lung Cancer
|
|
Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor
|
February 26, 2023
|
PC3I Authors Melina Marmarelis; Charu Aggarwal |
Journal of Thoracic Oncology
|
|
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma
|
March 10, 2023
|
PC3I Authors Melina Marmarelis |
JAMA Network Open
|
|
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90
|
March 19, 2023
|
PC3I Authors Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database
|
April 16, 2023
|
PC3I Authors Melina Marmarelis |
Cancer Medicine
|
|
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System
|
April 19, 2023
|
PC3I Authors Michelle Iocolano; Christopher A. D’Avella; Melina Marmarelis; Charu Aggarwal |
Clinical Lung Cancer
|
|
Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?
|
April 22, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis |
Journal of Thoracic Oncology
|
|
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
|
May 15, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Melina Marmarelis |
The Oncologist
|
|
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
|
June 4, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani |
JAMA Oncology
|
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
|
July 27, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Dylan G. Scholes; Peter Gabriel; Larry Shulman; Justin Bekelman |
JCO Precision Oncology
|
|
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
|
August 31, 2023
|
PC3I Authors Michelle Iocolano; Catherine Lai; Charu Aggarwal; Melina Marmarelis |
International Journal of Radiation Oncology, Biology, Physics
|
|
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
|
October 9, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella |
Clinical Lung Cancer
|
|
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
|
October 22, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis |
International Journal of Radiation Oncology, Biology, Physics
|
|
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
|
November 23, 2023
|
PC3I Authors Melina Marmarelis |
Lung Cancer
|
|
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
|
February 16, 2024
|
PC3I Authors Melina Marmarelis |
JTO Clinical and Research Reports
|
|
iNUDGE: Integration of liquid biopsy based next generation gene sequencing in newly diagnosed NSCLC—A stepped wedge cluster randomized clinical trial.
|
May 29, 2024
|
PC3I Authors Anthony Martella; Dylan G. Scholes; Meagan Hume; Charu Aggarwal; Christopher A. D’Avella; Ramy Sedhom; Peter Gabriel; Katharine Rendle; Justin Bekelman; Leland Boisseau; Melina Marmarelis |
Journal of Clinical Oncology
|
|
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial
|
July 3, 2024
|
PC3I Authors Melina Marmarelis; Dylan G. Scholes; Peter Gabriel; Anthony Martella; David Dougherty; Larry Shulman; Justin Bekelman; Charu Aggarwal |
JCO Oncology Practice
|
